Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH368144D
  • |
  • Pages: 64
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a biotechnology company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer. The company's bertilimumab is under clinical development for moderate to severe ulcerative colitis, crohn's disease and bullous pemphigoid. It also offers nanomabs, which is an antibody nanoparticle conjugate technology platform for the targeted delivery of chemotherapeutics. Immune Pharma's crolibulin is a small molecule vascular disrupting agent that is used for the treatment of solid tumors. The company develops drugs in the areas of immuno oncology, nano-dermatology and neuropathic pain. It has research and development facility in Herzliya-Pituach, Israel. Immune Pharma is headquartered in New York, the US.

Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Immune Pharma Acquires Rights to AMB8LK from MabLife

Partnerships

Immune Pharma Enters into Agreement with STC Biologics

Immune Pharma Plans to Partner with Hebrew University of Jerusalem

Immune Pharma Enters Into Co-Development Agreement With Yeda Research

Licensing Agreements

Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma

SATT Sud Est Enters into Licensing Agreement with Immune Pharma

Maxim Pharma Enters into Licensing Agreement with Immune Pharma

Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma

Immune Pharma Enters into Licensing Agreement with BioNanoSim

Immune Pharma Enters into Licensing Agreement with Yissum

Immune Pharma to Enter into Licensing Agreement with Yissum Research Development

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab

Immune Pharma Enters into Licensing Agreement with Atlante Biotech

Equity Offering

Immune Pharma Raises USD18 Million in Public Offering of Units

Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares

Immune Pharma to Spin-off its Cytovia

Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares

Immune Pharma Raises USD2 Million in Share Purchase Plan

Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares

Immune Pharma Completes Spin Off of Pain and Neurology Business

Immune Pharma Raises USD1 Million in Private Placement of Shares

Immune Pharma Raises USD0.8 Million in Private Placement of Shares

Immune Pharma Raises USD1 Million in Private Placement of Shares

Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock

Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million

Immune Pharma Raises USD1 Million in Private Placement of Units

Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants

Debt Offering

Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures

Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018

Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes

Acquisition

Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction

Immune Pharmaceuticals Inc-Key Competitors

Immune Pharmaceuticals Inc-Key Employees

Immune Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Strategy And Business Planning

Jul 19, 2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company

Financial Announcements

Nov 15, 2017: Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Aug 28, 2017: Immune Pharmaceuticals Provides Business Update and Summary of Recent Financial Highlights

Corporate Communications

Nov 27, 2017: Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer

Aug 14, 2017: Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer

Mar 13, 2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement

Jan 27, 2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors

Government and Public Interest

Apr 24, 2017: Immune Pharmaceuticals Announces Corporate Restructuring

Other Significant Developments

Aug 04, 2017: Immune Pharmaceuticals Issues Letter to Shareholders

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immune Pharma Acquires Rights to AMB8LK from MabLife

Immune Pharma Enters into Agreement with STC Biologics

Immune Pharma Plans to Partner with Hebrew University of Jerusalem

Immune Pharma Enters Into Co-Development Agreement With Yeda Research

Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma

SATT Sud Est Enters into Licensing Agreement with Immune Pharma

Maxim Pharma Enters into Licensing Agreement with Immune Pharma

Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma

Immune Pharma Enters into Licensing Agreement with BioNanoSim

Immune Pharma Enters into Licensing Agreement with Yissum

Immune Pharma to Enter into Licensing Agreement with Yissum Research Development

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab

Immune Pharma Enters into Licensing Agreement with Atlante Biotech

Immune Pharma Raises USD18 Million in Public Offering of Units

Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares

Immune Pharma to Spin-off its Cytovia

Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares

Immune Pharma Raises USD2 Million in Share Purchase Plan

Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares

Immune Pharma Completes Spin Off of Pain and Neurology Business

Immune Pharma Raises USD1 Million in Private Placement of Shares

Immune Pharma Raises USD0.8 Million in Private Placement of Shares

Immune Pharma Raises USD1 Million in Private Placement of Shares

Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock

Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million

Immune Pharma Raises USD1 Million in Private Placement of Units

Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants

Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures

Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018

Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes

Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction

Immune Pharmaceuticals Inc, Key Competitors

Immune Pharmaceuticals Inc, Key Employees

Immune Pharmaceuticals Inc, Other Locations

Immune Pharmaceuticals Inc, Subsidiaries

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com